期刊
BONE MARROW TRANSPLANTATION
卷 48, 期 12, 页码 1537-1542出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2013.98
关键词
amyloidosis; high-risk myeloma; melphalan; SCT; MEL100
资金
- National Cancer Institute, DHHS [CA32102, CA38926, CA37981, CA76448, CA35431, CA20319, CA76132, CA04919, CA46441, CA14028, CA58861, CA58416, CA12644, CA22433, CA46368, CA45377, CA35090, CA46113]
We designed a trial using two sequential cycles of modified high-dose melphalan at 100 mg/m(2) and autologous SCT (mHDM/SCT) in AL amyloidosis (light-chain amyloidosis, AL), AL with myeloma (ALM) and host-based high-risk myeloma (hM) patients through SWOG-0115. The primary objective was to evaluate OS. From 2004 to 2010, 93 eligible patients were enrolled at 17 centers in the United States (59 with AL, 9 with ALM and 25 with hM). The median OS for patients with AL and ALM was 68 months and 47 months, respectively, and has not been reached for patients with hM. The median PFS for patients with AL and ALM was 38 months and 16 months, respectively, and has not been reached for patients with hM. The treatment-related mortality (TRM) was 12% (11/93) and was observed only in patients with AL after SCT. Grade 3 and higher non-hematologic adverse events were experienced by 81%, 67% and 57% of patients with AL, ALM and hM, respectively, during the first and second HDM/SCT. This experience demonstrates that with careful selection of patients and use of mHDM for SCT in patients with AL, ALM and hM, even in the setting of a multicenter study, OS can be improved with acceptable TRM and morbidity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据